share_log

Truist Securities Maintains Buy on Collegium Pharmaceutical, Raises Price Target to $40

Benzinga ·  Feb 26 21:20

Truist Securities analyst Les Sulewski maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and raises the price target from $37 to $40.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment